<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002574</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02233</org_study_id>
    <secondary_id>MDA-DM-93151</secondary_id>
    <secondary_id>NCI-T93-0191D</secondary_id>
    <secondary_id>CDR0000063647</secondary_id>
    <nct_id>NCT00002574</nct_id>
  </id_info>
  <brief_title>Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>PHASE II STUDY OF SIMULTANEOUS HOMOHARRINGTONINE (NSC 141633) AND ALPHA INTERFERON (IFN-A) THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in&#xD;
      treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different&#xD;
      ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may&#xD;
      interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may&#xD;
      kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of homoharringtonine administered simultaneously with interferon&#xD;
      alpha in achieving complete cytogenetic response in patients with chronic myelogenous&#xD;
      leukemia in chronic phase.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH,&#xD;
      NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1994</start_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omacetaxine mepesuccinate</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Chronic myelogenous leukemia (CML) in chronic phase&#xD;
&#xD;
          -  Clonal evolution (i.e., the presence of clones other than the Ph chromosome) allowed&#xD;
             Ph chromosome variants or complex Ph chromosome translocations are not considered&#xD;
             disease acceleration&#xD;
&#xD;
          -  Ineligible for known therapy of higher efficacy or priority&#xD;
&#xD;
          -  Allogeneic bone marrow transplantation should be considered priority therapy for CML&#xD;
             patients with a matched related donor&#xD;
&#xD;
          -  No blastic phase CML (30% or more blasts in peripheral blood or bone marrow)&#xD;
&#xD;
          -  No accelerated phase CML, defined as any of the following: 15% or more peripheral or&#xD;
             marrow blasts or 30% or more blasts and promyelocytes 20% or more peripheral or marrow&#xD;
             basophils&#xD;
&#xD;
          -  Thrombocytopenia (platelets less than 100,000) unrelated to therapy&#xD;
&#xD;
          -  Documented extramedullary disease outside of liver or spleen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 15 and over&#xD;
&#xD;
          -  Performance status: Zubrod 0-2&#xD;
&#xD;
          -  Life expectancy: Sufficient to fully evaluate the effects of 2 courses of therapy&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT less than 300&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL OR creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No severe heart disease (class III/IV)&#xD;
&#xD;
          -  No pregnant or nursing women&#xD;
&#xD;
          -  Effective contraception required of fertile women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior interferon alpha&#xD;
&#xD;
          -  At least 2 weeks since antileukemic therapy, with recovery required&#xD;
&#xD;
          -  Patients who received hydroxyurea within the past 2 weeks and have WBC greater than&#xD;
             50,000 may enter protocol after discussion with the primary investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M. O'Brien, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2004</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Homoharringtonine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

